Pages that link to "Q35848663"
Jump to navigation
Jump to search
The following pages link to Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia (Q35848663):
Displaying 50 items.
- Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective (Q28388806) (← links)
- Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. (Q33684432) (← links)
- Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation (Q33685495) (← links)
- Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation (Q33802076) (← links)
- Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. (Q34164140) (← links)
- Does chemotherapy modify the immune surveillance of hematological malignancies? (Q34223517) (← links)
- Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein (Q34792248) (← links)
- NK cells and T cells cooperate during the clinical course of colorectal cancer (Q34933101) (← links)
- Clinical and biological predictors of outcome following relapse of CML post-allo-SCT (Q35054717) (← links)
- Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells (Q35591430) (← links)
- High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. (Q35900929) (← links)
- Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation (Q36006379) (← links)
- Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. (Q36185219) (← links)
- Implication of early lymphocyte recovery after allogeneic hematopoietic stem cell transplantation in children with leukemia (Q36463940) (← links)
- Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates (Q36661082) (← links)
- Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation in mouse and man. (Q36726230) (← links)
- Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation (Q36749321) (← links)
- Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population (Q36843807) (← links)
- Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation (Q36959201) (← links)
- Clinical strategies to enhance T cell reconstitution (Q36983263) (← links)
- Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib (Q37071112) (← links)
- Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. (Q37097120) (← links)
- Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors (Q37143051) (← links)
- Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies (Q37240985) (← links)
- Psychosocial factors and hematopoietic stem cell transplantation: potential biobehavioral pathways (Q37266089) (← links)
- What is the role for donor natural killer cells after nonmyeloablative conditioning? (Q37327327) (← links)
- Thymic involution and immune reconstitution. (Q37361275) (← links)
- CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. (Q37611172) (← links)
- Antileukemia and antitumor effects of the graft-versus-host disease: A new immunovirological approach (Q37823768) (← links)
- Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy (Q37942233) (← links)
- Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective (Q38285256) (← links)
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study (Q38376608) (← links)
- Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. (Q38742867) (← links)
- Use of natural killer cells as immunotherapy for leukaemia. (Q40047650) (← links)
- Antagonist effect of Interleukin 1 receptor on normal thymopoiesis and thymus toxicity of 5-azacytidine in mouse (Q40685825) (← links)
- Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation (Q41158988) (← links)
- Immunohematopoietic stem cell transplantation in Cape Town: a ten-year outcome analysis in adults. (Q45995264) (← links)
- The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. (Q52689883) (← links)
- Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease. (Q52763837) (← links)
- Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia. (Q53095522) (← links)
- Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome. (Q53255917) (← links)
- Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. (Q54495485) (← links)
- Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation (Q60455168) (← links)
- Fully functional NK cells after unrelated cord blood transplantation (Q62595290) (← links)
- Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. (Q64937145) (← links)
- Non-classical antileukemia activity of early recovering NK cells after induction chemotherapy and HLA-identical stem cell transplantation in myeloid leukemias (Q79817225) (← links)
- Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia (Q80731890) (← links)
- Lymphocyte subset recovery following allogeneic bone marrow transplantation: CD4(+)-cell count and transplant-related mortality (Q81436461) (← links)
- The Rapid Induction of HLA-E Is Essential for the Survival of Antigen-Activated Naive CD4 T Cells from Attack by NK Cells (Q85207178) (← links)
- Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations (Q85673872) (← links)